Who are Remifentanil, Dexmedetomidine, and Desflurane's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Remifentanil, propofol and citanest, Sevoflurane+Propofol, Anesthesia maintenance , propofol,remifentanil,cisatracurium, Ketofol as induction agent, Remifentanil, Propofol, and Desflurane, propofol，remifentanil，cis atracurium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/remifentanil-dexmedetomidine-and-desflurane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Remifentanil, Dexmedetomidine, and Desflurane — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remifentanil, Dexmedetomidine, and Desflurane (Remifentanil, Dexmedetomidine, and Desflurane) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic combination. Area: Anesthesiology.

marketed General anesthetic combination Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Remifentanil, Dexmedetomidine, and Desflurane (Remifentanil, Dexmedetomidine, and Desflurane) — The Cooper Health System. This is a combination of three anesthetic agents that work synergistically: remifentanil (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and desflurane (volatile anesthetic) to produce sedation, analgesia, and unconsciousness for surgical procedures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Remifentanil, Dexmedetomidine, and Desflurane TARGET	Remifentanil, Dexmedetomidine, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)
Remifentanil, propofol and citanest	Remifentanil, propofol and citanest	University of Aarhus	marketed	General anesthetic combination	Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)
Sevoflurane+Propofol	Sevoflurane+Propofol	Huazhong University of Science and Technology	marketed	General anesthetic combination	GABA-A receptor
Anesthesia maintenance , propofol,remifentanil,cisatracurium	Anesthesia maintenance , propofol,remifentanil,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Ketofol as induction agent	Ketofol as induction agent	Fayoum University Hospital	marketed	General anesthetic combination	NMDA receptor antagonist (ketamine) and GABA-A receptor agonist (propofol)
Remifentanil, Propofol, and Desflurane	Remifentanil, Propofol, and Desflurane	The Cooper Health System	marketed	General anesthetic combination	Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
propofol，remifentanil，cis atracurium	propofol，remifentanil，cis atracurium	Tang-Du Hospital	marketed	General anesthetic combination (GABA agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic combination class)

The Cooper Health System · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
Huazhong University of Science and Technology · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
University of Aarhus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remifentanil, Dexmedetomidine, and Desflurane — Competitive Intelligence Brief. https://druglandscape.com/ci/remifentanil-dexmedetomidine-and-desflurane. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab